Published in J Hematol Oncol on June 01, 2009
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol (2010) 2.94
Vorinostat in solid and hematologic malignancies. J Hematol Oncol (2009) 1.42
Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta (2010) 1.35
Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol Dis (2011) 1.29
Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. J Hematol Oncol (2010) 1.18
Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells. Trends Mol Med (2009) 1.07
Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation. Discov Med (2010) 1.03
Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax. Antimicrob Agents Chemother (2010) 0.99
Cancer epigenetics: above and beyond. Toxicol Mech Methods (2011) 0.95
Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma. J Hematol Oncol (2013) 0.94
Epigenetics and cancer. J Appl Physiol (1985) (2010) 0.93
Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Curr Pharm Des (2013) 0.91
Lung cancer: a modified epigenome. Cell Adh Migr (2010) 0.89
Cancer cells' epigenetic composition and predisposition to histone deacetylase inhibitor sensitization. Epigenomics (2011) 0.87
Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies? J Biomed Biotechnol (2010) 0.86
Selenium-containing histone deacetylase inhibitors for melanoma management. Cancer Biol Ther (2012) 0.86
Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Lett (2012) 0.86
Effect of phenylhexyl isothiocyanate on aberrant histone H3 methylation in primary human acute leukemia. J Hematol Oncol (2012) 0.84
Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis. BMC Med (2016) 0.83
Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers. Future Oncol (2011) 0.81
Interaction between ZBP-89 and p53 mutants and its contribution to effects of HDACi on hepatocellular carcinoma. Cell Cycle (2012) 0.81
Epigenetics and Cellular Metabolism. Genet Epigenet (2016) 0.80
Reactivating aberrantly hypermethylated p15 gene in leukemic T cells by a phenylhexyl isothiocyanate mediated inter-active mechanism on DNA and chromatin. J Hematol Oncol (2010) 0.79
The effect of CTB on P53 protein acetylation and consequence apoptosis on MCF-7 and MRC-5 cell lines. Adv Biomed Res (2013) 0.79
Preclinical cancer chemoprevention studies using animal model of inflammation-associated colorectal carcinogenesis. Cancers (Basel) (2012) 0.78
Combination of Salermide and Cholera Toxin B Induce Apoptosis in MCF-7 but Not in MRC-5 Cell Lines. Int J Prev Med (2013) 0.76
Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment. J Hematol Oncol (2017) 0.75
Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand. J Hematol Oncol (2010) 0.75
Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells. J Cancer Res Clin Oncol (2011) 0.75
Epigenetic therapy in human choriocarcinoma. Cancers (Basel) (2010) 0.75
Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol (2002) 9.83
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer (2006) 8.57
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood (2006) 8.38
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (1999) 7.47
Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene (2007) 7.13
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J (2001) 6.85
Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov (2006) 6.39
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol (2005) 4.99
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood (2006) 4.92
Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res (2007) 4.91
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem (2005) 4.62
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol (2007) 4.61
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res (2003) 4.55
Discovery and development of SAHA as an anticancer agent. Oncogene (2007) 3.58
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A (1999) 3.26
The role of DNA methylation in setting up chromatin structure during development. Nat Genet (2003) 3.06
Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res (2006) 2.61
Prospects: histone deacetylase inhibitors. J Cell Biochem (2005) 2.46
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res (2006) 2.33
Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol (2005) 2.29
FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) (1994) 2.28
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood (2007) 2.15
The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med (2006) 2.11
Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. Nutr Cancer (2006) 2.10
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma (2008) 2.09
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood (2008) 2.04
Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs (2005) 2.03
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res (2007) 2.00
A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res (2008) 1.89
Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther (2003) 1.87
Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol (2005) 1.81
CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia (2007) 1.79
FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res (1998) 1.78
A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol (2008) 1.72
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer (2006) 1.65
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs (2007) 1.53
Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer (2008) 1.52
Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer (2007) 1.52
Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest (2004) 1.51
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol (2008) 1.49
A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res (2001) 1.49
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2008) 1.42
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol (2008) 1.42
The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene (2004) 1.38
Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer (2005) 1.38
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs (2008) 1.36
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res (2008) 1.36
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res (2001) 1.34
Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res (2008) 1.34
A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res Treat (2003) 1.32
MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent. Int J Biochem Cell Biol (2007) 1.31
Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol Cancer Ther (2007) 1.29
A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer (2006) 1.25
Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res (2004) 1.24
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer (2005) 1.24
Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia (2006) 1.22
Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer (2006) 1.21
De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol (2008) 1.19
Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res (2008) 1.14
Ingestion of an isothiocyanate metabolite from cruciferous vegetables inhibits growth of human prostate cancer cell xenografts by apoptosis and cell cycle arrest. Carcinogenesis (2004) 1.13
Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res (2001) 1.13
Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells. Int J Oncol (2006) 1.11
ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J Cancer Res Clin Oncol (2008) 1.11
Chronic oral administration of CI-994: a phase 1 study. Invest New Drugs (2001) 1.10
CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther (2006) 1.09
Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer. Mol Carcinog (2007) 1.09
Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J Med Chem (2008) 1.08
A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann Hematol (2009) 1.06
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs (2006) 1.05
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res (2008) 1.05
Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells. Cancer Chemother Pharmacol (2006) 0.92
Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. J Hematol Oncol (2008) 0.89
Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma. Mol Cancer Ther (2003) 0.88
Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agents. J Clin Oncol (2008) 0.88
Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor. Expert Opin Investig Drugs (2008) 0.88
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol (2004) 0.85
Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer. Anticancer Res (2007) 0.85
The phenylhexyl isothiocyanate induces apoptosis and inhibits leukemia cell growth in vivo. Oncol Rep (2006) 0.84
Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824. Novartis Found Symp (2004) 0.83
Clinical advances in hypomethylating agents targeting epigenetic pathways. Curr Cancer Drug Targets (2010) 0.81
Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer. Cancer J (2003) 0.79
The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia? Leukemia (2004) 0.78
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood (2010) 5.95
Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med (2015) 3.42
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol (2010) 2.94
Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica (2006) 2.75
Critical Role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. Immunity (2012) 2.16
Nuclear miRNA regulates the mitochondrial genome in the heart. Circ Res (2012) 1.95
Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol (2013) 1.92
MEK and the inhibitors: from bench to bedside. J Hematol Oncol (2013) 1.90
Fetal mouse phthalate exposure shows that Gonocyte multinucleation is not associated with decreased testicular testosterone. Toxicol Sci (2007) 1.75
Current management and novel agents for malignant melanoma. J Hematol Oncol (2012) 1.53
Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res (2013) 1.43
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol (2010) 1.40
Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol (2012) 1.30
Reversal in multidrug resistance by magnetic nanoparticle of Fe3O4 loaded with adriamycin and tetrandrine in K562/A02 leukemic cells. Int J Nanomedicine (2008) 1.29
Current management and prognostic features for gastrointestinal stromal tumor (GIST). Exp Hematol Oncol (2012) 1.23
p38 mitogen-activated protein kinase plays an inhibitory role in hepatic lipogenesis. J Biol Chem (2006) 1.23
Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. J Hematol Oncol (2010) 1.18
STAT inhibitors for cancer therapy. J Hematol Oncol (2013) 1.16
Recent advances and novel agents for gastrointestinal stromal tumor (GIST). J Hematol Oncol (2012) 1.16
Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clin Cancer Res (2011) 1.14
Human parvovirus B19 causes cell cycle arrest of human erythroid progenitors via deregulation of the E2F family of transcription factors. J Clin Invest (2010) 1.14
B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol (2013) 1.14
Ingestion of an isothiocyanate metabolite from cruciferous vegetables inhibits growth of human prostate cancer cell xenografts by apoptosis and cell cycle arrest. Carcinogenesis (2004) 1.13
Targeting cell cycle machinery as a molecular mechanism of sulforaphane in prostate cancer prevention. Int J Oncol (2004) 1.12
Dietary nitrate and nitrite modulate blood and organ nitrite and the cellular ischemic stress response. Free Radic Biol Med (2009) 1.12
Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells. Int J Oncol (2006) 1.11
A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol (2011) 0.99
Microarray-based characterization of a colony assay used to investigate endothelial progenitor cells and relevance to endothelial function in humans. Arterioscler Thromb Vasc Biol (2009) 0.99
Testicular gene expression profiling following prepubertal rat mono-(2-ethylhexyl) phthalate exposure suggests a common initial genetic response at fetal and prepubertal ages. Toxicol Sci (2006) 0.99
P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol (2008) 0.95
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol (2012) 0.94
Sox4 cooperates with PU.1 haploinsufficiency in murine myeloid leukemia. Blood (2011) 0.92
Side effects related to cancer treatment: CASE 2. Splenic rupture following pegfilgrastim. J Clin Oncol (2005) 0.92
Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors. Drug Des Devel Ther (2009) 0.91
A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. J Hematol Oncol (2012) 0.91
Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. J Hematol Oncol (2008) 0.89
CD146+ T lymphocytes are increased in both the peripheral circulation and in the synovial effusions of patients with various musculoskeletal diseases and display pro-inflammatory gene profiles. Cytometry B Clin Cytom (2010) 0.89
Phase I study of temozolomide in relapsed/refractory acute leukemia. J Clin Oncol (2002) 0.86
The phenylhexyl isothiocyanate induces apoptosis and inhibits leukemia cell growth in vivo. Oncol Rep (2006) 0.84
Palladium-catalyzed allylic alkylation of simple ketones with allylic alcohols and its mechanistic study. Angew Chem Int Ed Engl (2014) 0.84
Severe toxicity following induction chemotherapy for acute myelogenous leukemia in a patient with Werner's syndrome. Leuk Lymphoma (2005) 0.84
miR-222 contributes to sex-dimorphic cardiac eNOS expression via ets-1. Physiol Genomics (2013) 0.84
High fat diet reduces the expression of glutathione peroxidase 3 in mouse prostate. Prostate (2011) 0.82
Efficient palladium-catalyzed asymmetric allylic alkylation of ketones and aldehydes. Org Biomol Chem (2011) 0.80
PET scan-positive cat scratch disease in a patient with T cell lymphoblastic lymphoma. Leuk Res (2005) 0.80
C-N bond cleavage of allylic amines via hydrogen bond activation with alcohol solvents in Pd-catalyzed allylic alkylation of carbonyl compounds. J Am Chem Soc (2011) 0.79
Deficient histone acetylation in acute leukemia and the correction by an isothiocyanate. Acta Haematol (2009) 0.79
Acute promyelocytic leukemia with tetraploid karyotype: first report in the Western hemisphere and update of previous reports. Leuk Res (2011) 0.79
T-cryptantigen (TCA) activation in sever pneumonia complicated with multiple organ failure. Transfus Apher Sci (2010) 0.79
[Coblation-assisting uvulopalatopharyngoplasty combining coblation-channeling of the tongue for patients with severe OSAHS]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2012) 0.78
Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials. Biomark Res (2013) 0.78
Novel influenza A (H1N1) in patients with hematologic malignancies. J Clin Oncol (2009) 0.77
Coexistence of inversion 16 and the Philadelphia chromosome in patients with acute myelogenous leukemia. Leuk Lymphoma (2002) 0.77
[Modulation of histone acetylation and induction of apoptosis in SMMC-7721 cells by phenylhexyl isothiocyanate]. Zhonghua Zhong Liu Za Zhi (2010) 0.76
Prospective evaluation of 2009 H1N1 influenza A in patients admitted with fever to an oncology unit. Infect Control Hosp Epidemiol (2011) 0.76
t(3;9;22) 3-way chromosome translocation in chronic myeloid leukemia is associated with poor prognosis. Cancer Invest (2009) 0.76
Hydrogen-bond-activated palladium-catalyzed allylic alkylation via allylic alkyl ethers: challenging leaving groups. Org Lett (2014) 0.76
Very late relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Leuk Res (2009) 0.76
Journal of hematology & oncology: a journal open to all. J Hematol Oncol (2008) 0.75
Phenotypic and functional characterization of a mouse model of targeted Pig-a deletion in hematopoietic cells. Haematologica (2009) 0.75
Mechanism and early intervention research on ALI during emergence surgery of Stanford type-A AAD: Study protocol for a prospective, double-blind, clinical trial. Medicine (Baltimore) (2016) 0.75
Sweet fruit from a poisonous kiss. J Hematol Oncol (2010) 0.75
Severe imatinib-associated muscle edema in patients with chronic myelogenous leukemia and marked leukocytosis. Leuk Lymphoma (2008) 0.75
[Analysis of CYP21A2 gene mutations in two families with 21-hydroxylase deficiency]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi (2014) 0.75
Highly efficient asymmetric Michael addition of aldehyde to nitroolefin using perhydroindolic acid as a chiral organocatalyst. Org Biomol Chem (2012) 0.75
[Preliminary clinical investigation of coblation-assisted functional endoscopic sinus surgery for chronic sinusitis and nasal polyps]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2011) 0.75
Asymmetric hydrogenation of β-amino ketones with the bimetallic complex RuPHOX-Ru as the chiral catalyst. Org Biomol Chem (2013) 0.75
Palladium-catalyzed asymmetric hydrogenation of α-acyloxy-1-arylethanones. Angew Chem Int Ed Engl (2013) 0.75
[Low-temperature plasma assisted via mouth for surgery treating styloid process syndrome]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2012) 0.75
[Clinical observation of coblation under endoscopy on epiglottis cyst]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2014) 0.75
[Advances in treatment of congenital posterior choanal atresia]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2016) 0.75
[Coblation for benign hyperplasia of tongue base under endoscope]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2009) 0.75
Iridium-catalyzed allyl-allyl cross-coupling of allylic carbonates with (E)-1,3-diarylpropenes. Chem Commun (Camb) (2015) 0.75
[EFFECTIVENESS OF POSTERIOR UNILATERAL TRANSPEDICULAR DEBRIDEMENT, BONE GRAFT FUSION, AND PEDICLE SCREW FIXATION FOR THORACOLUMBAL TUBERCULOSIS]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi (2015) 0.75
[Expression of BDNF and trk B in the cochleas of the aged rats]. Lin Chuang Er Bi Yan Hou Ke Za Zhi (2006) 0.75
Asymmetric domino reaction of cyclic N-sulfonylimines and simple aldehydes with trans-perhydroindolic acid as an organocatalyst. Org Lett (2014) 0.75
Pd-catalyzed asymmetric allylic amination using easily accessible metallocenyl P,N-ligands. Org Biomol Chem (2015) 0.75
[Revaluvation of UPPP and the pharynx in patients with snoring anatomy]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2015) 0.75
[Investigation of reoperation after failure of UPPP]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2009) 0.75
Asymmetric tandem reactions of N-sulfonylimines and α,β-unsaturated aldehydes: an alternative reaction pathway to that of using saturated aldehydes. Chem Commun (Camb) (2014) 0.75
Evaluation of temozolomide in patients with myelodysplastic syndrome. Leuk Lymphoma (2004) 0.75
[Lingual thyroglossal duct cyst treatment by low temperature coblation on endoscope]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2014) 0.75
Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution. Leuk Lymphoma (2006) 0.75
[Coblation-channelling for the tongue]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2014) 0.75
The synthesis of chiral β-aryl-α,β-unsaturated amino alcohols via a Pd-catalyzed asymmetric allylic amination. Org Biomol Chem (2013) 0.75
Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock. Front Med (2014) 0.75
Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestine. Leuk Lymphoma (2007) 0.75
P-stereogenic PNP pincer-Pd catalyzed intramolecular hydroamination of amino-1,3-dienes. Org Biomol Chem (2015) 0.75
Publish, not perish: Introducing Experimental Hematology & Oncology. Exp Hematol Oncol (2012) 0.75